

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Efficacy of high dose cholecalciferol on smear positive pulmonary tuberculosis treatment

Protocol summary

Summary

(1) The study is aimed to assess the effect of high dose vitamin D on treatment of pulmonary tuberculosis (with a hypothesis that high dose vitamin D speeds up the recovery) (2) Study Design: A double blind parallel randomized clinical trial lasting about one year or until total cases and controls are 100 patients (3) Study: Patients referred to pulmonary disease clinic of Bandar Abbas Health care center who meet the inclusion criteria, select a blue or red colored paper to be allocated in case or control group. According to the color of the paper the physician, gives the patient a package containing standard antituberculous regimen with vitamin D or placebo according to the color of the paper unaware of the contents. Prior to initiation of the treatment, a base line CBC, LFT, BUN, Cr, HIV Elisa, PTH, sputum smear and CXR are taken. Sputum smear is repeated on 2nd, 3rd, 4th, 5th and 6 month of therapy. Finally in the 6th month of treatment a CXR is taken. The patients are advised to refrain from taking Mg containing anti-acids (4) The participants meeting the inclusion criteria (1)Age 18-65 yrs 2)Inclining to participate in the study 3)Smear positive pulmonary tuberculosis 4)Anti-tuberculous regimen has not started 5)Not consuming vitamin D complements) are included in the study and are excluded from the study if meet any of the following criteria (1) Positive history of anti-tuberculous treatment 2)Extrapulmonary tuberculosis 3)Immunosuppression, HIV / AIDS, renal insufficiency, hepatic insufficiency, diabetes, organ transplant, sarcoidosis, hyperparathyroidism 4)Treatment with thiazides or corticosteroids 5)Lactation or pregnancy 6) Symptomatic cardiac disease 7)Allergy to anti tuberculous medications or intolerance to complete the treatment 7)Concomitant use of drugs interacting with serum Vitamin D levels such as Phenytoin, Phenobarbital, Carbamazepin, Theophylline 8) death (5) Intervention: Vitamin D 50000 IU/day from DANA pharmaceuticals and the placebo is also produced by DANA pharmaceuticals. The red paper is for

the intervention group and the blue paper is for the placebo group (6) Outcome: main outcome is considered sputum and chest x ray clearance as indicators of cure

General information

Acronym

HDC-PTB

IRCT registration information

IRCT registration number: **IRCT2013061610326N1**

Registration date: **2013-08-26, 1392/06/04**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2013-08-26, 1392/06/04

Registrant information

Name

Tasnim Eghbal Eftekhari

Name of organization / entity

Hormozgan University of Medical Sciences,
Department of Research and Technology

Country

Iran (Islamic Republic of)

Phone

+98 76 1333 7192

Email address

teftekhari@hums.ac.ir

Recruitment status

Recruitment complete

Funding source

Hormozgan University of Medical Sciences, Department of Research and Technology

Expected recruitment start date

2013-09-23, 1392/07/01

Expected recruitment end date

2014-09-23, 1393/07/01

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Efficacy of high dose cholecalciferol on smear positive pulmonary tuberculosis treatment

Public title
Efficacy of high dose vitamin d on smear positive pulmonary tuberculosis treatment

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria: 1- age of 18-65 years 2- inclined to participate in the study 3- smear positive pulmonary tb 4- has not started antituberculous treatment 5- does not use vitamin d supplement Exclusion criteria: 1- use of antituberculous treatment regimen 2-extrapulmonary or smear negative tb 3-immunosuppression, HIV/AIDS, renal insufficiency, hepatic failure, diabetes, organ transplant, sarcoidosis, hyperparathyroidism 5- treatment with corticosteroids, thiazides 6-symptomatic cardiac disease 7- allergy to antituberculous medications or intolerance to complete the treatment 8-concomitant consumption of drugs interacting with vitamin d levels (i.e phenytoin, phenobarbital, carbamazepin, theophylline) 9-unable to give consent to participate in the study or inability to complete the study 10-Death of the patient

Age
From **18 years** old to **65 years** old

Gender
Both

Phase
2-3

Groups that have been masked
No information

Sample size
Target sample size: **100**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Double blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee
Name of ethics committee
Hormozgan University of Medical Sciences
Street address
Shahid Mohammadi Hospital- Research and Technology Department
City
Bandar Abbas
Postal code
7919915519
Approval date
2013-05-22, 1392/03/01
Ethics committee reference number
1156

Health conditions studied

1

Description of health condition studied
Smear positive pulmonary tuberculosis
ICD-10 code
A15.0
ICD-10 code description
Tuberculosis of lung, confirmed by sputum microscopy with or without culture

Primary outcomes

1

Description
Sputum conversion
Timepoint
At the initiation of treatment and six months after
Method of measurement
Sputum smear

Secondary outcomes
empty

Intervention groups

1

Description
Control Group: Placebo (manufactured by DANA pharmaceuticals) for 6 months PO for 6 months.
Category
Treatment - Drugs

2

Description
case group: vit D3 capsule: 50000IU/day PO,(manufactured by Dana Pharmaceuticals) for 6 months
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Bandar Abbas Health center, Pulmonary disease center

Full name of responsible person**Street address****City**

Bandar Abbas

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Hormozgan University of Medical Sciences, research and technology department

Full name of responsible person

Mirza ali Nazarnezhad

Street address

Jomhuri Blvd, Shahid Mohammadi hospital, research and technology department

City

Bandar abbas

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Hormozgan University of Medical Sciences, research and technology department

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries

Contact**Name of organization / entity**

Hormozgan University of Medical Sciences, research and technology department

Full name of responsible person

Tasnim Eghbal Eftekhaari

Position

Scientometrics Director

Other areas of specialty/work**Street address**

Shahid Mohammadi hospital, research and technology department

City

Bandar abbas

Postal code

79199155519

Phone

+98 76 1333 7192

Fax**Email**

tasnim.eftekhaari@gmail.com, teftekhari@hums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Hormozgan University of Medical Sciences

Full name of responsible person

Seyede Tasnim Eghbal Eftekhaari

Position

Molecular Medicine research fellow

Other areas of specialty/work**Street address**

Shahid Mohammadi hospital, research and technology department

City

Bandar abbas

Postal code**Phone**

+98 76 1333 7379

Fax**Email**

tasnim.eftekhaari@gmail.com

Web page address

Person responsible for updating data

Contact**Name of organization / entity**

Hormozgan University of Medical Sciences

Full name of responsible person

Seyede Tasnim Eghbal Eftekhari

Position

Scientometrics Director

Other areas of specialty/work**Street address**

Shahid Mohammadi hospital, research and technology department

City

Bandar abbas

Postal code**Phone**

+98 76 1333 7379

Fax**Email**

tasnim.eftekhaari@gmail.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol*empty***Statistical Analysis Plan***empty***Informed Consent Form***empty***Clinical Study Report***empty***Analytic Code***empty***Data Dictionary***empty*